ArticleFrontiers in immunology2024
The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells.
Remo Poto et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
11 papers cite it
this papercites it